Impact of Smokeless Oral Nicotine Products on Cardiovascular Disease
Published: December 03, 2024
- This policy statement summarizes: existing evidence regarding the complex relationships between smokeless oral nicotine products, cardiovascular disease and public health; the evolving product marketplace which now includes nicotine pouch products and synthetic nicotine; and the use of these products among adults and youth.
- This statement examines the landscape of smokeless oral nicotine products and identifies critical research needs for better understanding their impact on public health. Further research is needed to: better understand initiation and use, patterns of addiction, the influence of smokeless oral nicotine products on continued tobacco use, including dual or poly-use, evaluate the health impact of long-term use on population health, and identify public health interventions to reduce use prevalence.
- The AHA identifies several public policy levers that will reduce the use of smokeless oral nicotine and other tobacco products. Also highlighting the critical role of clinicians in preventing use and helping smokeless oral nicotine product users quit.